Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
The Journal of Biological Chemistry|May 6, 2023
The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signalingJocelyne Lopez, Daniel A Bonsor, Matthew J Sale, et al.Journal of Cell Science|December 24, 2013
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translationClaire L Cope, Rebecca Gilley, Kathryn Balmanno, et al.Science Signaling|June 17, 2011
A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. CookAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.Science Signaling|March 31, 2011
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cellsAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.Oncogene|October 8, 2024
Inhibition and degradation of NRAS with a pan-NRAS monobodyMichael Whaby, Gayatri Ketavarapu, Akiko Koide, et al.Proceedings of the National Academy of Sciences of the United States of America|June 30, 2025
A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous systemHarish N Vasudevan, Nadia Arang, Maria Sacconi Nunez, et al.Proceedings of the National Academy of Sciences of the United States of America|August 12, 2021
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activityPau Castel, Srisathiyanarayanan Dharmaiah, Matthew J Sale, et al.Science Advances|July 14, 2023
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophyAntonio Cuevas-Navarro, Morgan Wagner, Richard Van, et al.British Journal of Cancer|December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer modelsClaudia Winkler, Joshua Armenia, Gemma N Jones, et al.Proceedings of the National Academy of Sciences of the United States of America|January 23, 2023
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerizationLucy C Young, Ruby Goldstein de Salazar, Sae-Won Han, et al.Pageof 3